<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01932437</url>
  </required_header>
  <id_info>
    <org_study_id>AH106</org_study_id>
    <nct_id>NCT01932437</nct_id>
  </id_info>
  <brief_title>Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elusys Therapeutics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elusys Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, local tolerability, pharmacokinetics (PK) and
      immunogenicity of escalating single intramuscular (IM) doses of ETI-204 in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following completion of a Screening visit subjects will arrive at the clinic on Day -1. On
      Day 1, subjects will be randomized in a 3:1 ratio to receive an IM dose of either ETI-204 or
      matching placebo, respectively:

      Cohort 1: 4 subjects randomized to 4 mg/kg ETI-204 or matching placebo Cohort 2: 8 subjects
      randomized to 8 mg/kg ETI-204 or matching placebo Cohort 3: 8 subjects randomized to 16 mg/kg
      ETI-204 or matching placebo Cohort 4: 8 subjects randomized to 20 mg/kg ETI-204 or matching
      placebo Cohort 5: 8 subjects randomized to 24 mg/kg ETI-204 or matching placebo

      Study drug will be injected bilaterally into the vastus lateralis muscles, with the subject
      in a supine position. A separate syringe with a 21-gauge,1.5-inch needle will be used for
      each injection. The number of injections and injection volume will increase with increasing
      dose allowing for an assessment of increasing IM ETI-204 doses and the tolerability of a
      larger number of injections and larger injection volume.

      Subjects will be pretreated with 50 mg oral diphenhydramine approximately 30 minutes prior to
      administration of study drug.

      Subjects will be discharged from the study facility on Day 4 following completion of study
      assessments and will return to the study facility for additional visits on Days 7, 10, 15 (±3
      days), 29 (±3 days), 43 (±3 days), and 71 (±4 days).

      Decisions to dose-escalate will be made by the investigator(s) in conjunction with the
      sponsor and will be based solely on the available safety and local tolerability data up to
      and including Day 4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2013</start_date>
  <completion_date type="Actual">July 3, 2014</completion_date>
  <primary_completion_date type="Actual">July 3, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The investigator, clinical research unit staff, and subjects will be blinded to treatment assignment. The randomization list will be made available to the pharmacist preparing study drug.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Adverse Events</measure>
    <time_frame>Up to 71 (+/- 4) days or for 30 additional days after the final study visit for subjects with ongoing adverse events at the final scheduled study visit, for each group.</time_frame>
    <description>Safety was assessed for all subjects in the Safety Population by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical examinations, injection site assessments, skin assessments for presence/absence of rash, and adverse events (AEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration of ETI-204 (Cmax)</measure>
    <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
    <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration of ETI-204 (Tmax)</measure>
    <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
    <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last)</measure>
    <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
    <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
    <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
    <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F)</measure>
    <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
    <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-ETI-204 Antibodies</measure>
    <time_frame>Pre-dose and on Days 10, 43, and 71 after the IM injection of ETI-204 or placebo on Day 1.</time_frame>
    <description>Blood samples were collected and serum samples were assayed at an initial dilution of 1:10. Samples that were positive at the 1:10 dilution were serially diluted 1:2 and assayed until a negative result was attained. The titer of the most dilute sample yielding a positive result was recorded as the titer for that time point. Immunogenicity was measured by the number of participants in each study arm with anti-ETI-204 antibody values at Days 8, 43 or 71 ≥ 4-times higher than at baseline, or if the titer was negative at baseline, the post-treatment sample(s) required a titer of at least 1:20 for it to be considered positive.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Inhalational Anthrax</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 subjects will receive an IM dose of 4 mg/kg ETI-204, administered as two injections with a maximum volume of 2 mL at each injection site.
1 subject will receive an IM dose of ETI-204-placebo in an identical fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects will receive an IM dose of 8 mg/kg ETI-204, administered as two injections with a maximum volume of 4 mL at each injection site.
2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects will receive an IM dose of 16 mg/kg ETI-204, administered at four sites, with administration of 4 mL at one site and the remaining volume given in three additional injections with a maximum volume of 4 mL at each injection site.
2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects will receive an IM dose of 20 mg/kg ETI-204, administered at up to five sites, with the injection volume distributed equally between injections and a maximum volume of 4 mL per injection site.
2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects will receive an IM dose of 24 mg/kg ETI-204, administered at up to six sites, with administration of 5 mL at one site and the remaining volume given in up to five additional injections distributed equally with a maximum volume of 4 mL per injection site.
2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETI-204</intervention_name>
    <description>monoclonal antibody</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>Obiltoxaximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for ETI-204</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females or males ≥18 years of age;

          2. All females regardless of childbearing potential must have a negative serum beta human
             chorionic gonadotropin (β-hCG) pregnancy test at Screening and Day -1;

          3. Females of childbearing potential (i.e., not postmenopausal or surgically sterile)
             must agree to practice abstinence or to use a medically accepted method of
             contraception from the time of Screening through 30 days after the final study visit.
             Acceptable methods of contraception include diaphragm/cervical cap with spermicide;
             sponge with spermicide; condom with spermicide; or intrauterine device with condom or
             spermicide. The following contraceptive methods are acceptable only when used with a
             condom and spermicide: birth control pills, birth control patches, vaginal ring,
             hormone under the skin, or hormone injections;

          4. Postmenopausal females, defined as females who have had amenorrhea for at least 12
             months either naturally or following cessation of all exogenous hormonal treatments,
             and have a follicle stimulating hormone level of &gt;40 mIU/mL at Screening;

          5. Females who have undergone surgical sterilization, including hysterectomy, bilateral
             oophorectomy, bilateral salpingectomy, tubal ligation, or tubal essure;

          6. Males must agree to practice abstinence or use a condom with spermicide and to refrain
             from sperm donation from Screening during the study and for 30 days after the final
             study visit;

          7. Provide written informed consent;

          8. Willing to comply with study restrictions.

        Exclusion Criteria:

          1. Body weight &gt;100 kg;

          2. Body mass index ≥32 kg/m2;

          3. Pregnant or lactating female;

          4. Clinically significant comorbidity that would interfere with completion of the study
             procedures or objectives, or compromise the subject's safety;

          5. Supine systolic blood pressure (BP) ≥150 mmHg or ≤90 mmHg or diastolic BP ≥95 mmHg;

          6. Use of H1 receptor antagonists (i.e., antihistamines) within 5 days prior to Day 1;

          7. Evidence of drug or alcohol abuse within 6 months of Day 1 as determined by the
             Investigator;

          8. Positive test result for drugs of abuse (with the exception of medically prescribed
             drugs) at Screening or on Day -1;

          9. Positive test for alcohol at Screening, subject to Investigator's discretion. Subjects
             who test positive for alcohol at Day -1 are excluded from the study;

         10. Treatment with an investigational agent within 30 days or 5 half-lives of the
             investigational agent at Day 1 (whichever is longer);

         11. Congenital or acquired immunodeficiency syndrome;

         12. Prior solid organ or bone marrow transplant;

         13. Positive test for Hepatitis B (surface antigen), Hepatitis C, or human
             immunodeficiency virus (HIV) at Screening;

         14. History of prior treatment for anthrax exposure or prior anthrax infection;

         15. Prior immunization with any approved or investigational anthrax vaccine or prior
             treatment with an investigational anthrax treatment (e.g., ETI-204, raxibacumab, or
             anthrax immune globulin);

         16. Military personnel deployed in 1990 or after, unless the subject can provide
             documentation demonstrating he or she has not previously received any approved or
             investigational anthrax vaccine;

         17. Use of systemic steroids, immunosuppressive agents, anticoagulants, or
             anti-arrhythmics within 1 year prior to Day 1. A single short course (i.e., less than
             14 days) of systemic steroid therapy is allowed, provided it concluded more than 6
             months prior to Day 1;

         18. Donation or loss of &gt;500 mL of blood within 30 days or plasma within 7 days of Day 1;

         19. Prior stroke, epilepsy, relapsing or degenerative central nervous system disease, or
             relapsing or degenerative ocular disease;

         20. Myocardial infarction or acute coronary syndrome in the past 5 years, active angina
             pectoris, or heart failure (New York Heart Association scale &gt;1);

         21. History of chronic liver disease;

         22. Calculated creatinine clearance of &lt;30 mL/min using the Cockcroft-Gault equation;

         23. Any clinically significant abnormality, in the Investigator's opinion, on
             electrocardiogram (ECG) or clinical laboratory tests (hematology, clinical chemistry,
             or urinalysis) at Screening. Out of range tests may be repeated to confirm;

         24. History of allergic or hypersensitivity reaction or hives to other therapeutic
             antibodies or immunoglobulins;

         25. History of any malignant neoplasm within the last 5 years, with the exception of
             adequately treated localized or in situ non-melanoma carcinoma of the skin (e.g.,
             basal cell carcinoma) or the cervix;

         26. Subjects who, in the opinion of the Investigator, are not suitable candidates for
             enrollment or who may not comply with the requirements of the study.

         27. Platelet count &lt;140 K/µL;

         28. Prothrombin time/international normalized ratio or activated partial thromboplastin
             time &gt;1.2 X the upper limit of normal at Screening or Day -1;

         29. Poor muscle mass as determined by the Investigator;

         30. Family or personal history of a bleeding disorder;

         31. History of unexplained bleeding;

         32. Use of any anticoagulant or anti-platelet drug for 3 months prior to Screening. At the
             discretion of the Investigator, daily aspirin may be taken for general health reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex King, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2013</study_first_posted>
  <results_first_submitted>November 9, 2017</results_first_submitted>
  <results_first_submitted_qc>April 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2019</results_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monoclonal antibody, ETI-204, IM, safety, PK, immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study started July 26, 2013. Study completed July 03, 2014. Conducted at a Phase 1 Clinical Research Unit</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received a single intravenous dose of placebo on day 1 followed by a 71 day follow-up.</description>
        </group>
        <group group_id="P2">
          <title>ETI-204 4 mg/kg</title>
          <description>Participants received a single intravenous dose of ETI-204 4 mg/kg on day 1with a 71-day follow-up period.</description>
        </group>
        <group group_id="P3">
          <title>ETI-204 8 mg/kg</title>
          <description>Participants received a single intravenous dose of ETI-204 8 mg/kg on day 1 with a 71 day follow-up period.</description>
        </group>
        <group group_id="P4">
          <title>ETI-204 16 mg/kg</title>
          <description>Participant received a single intravenous dose of ETI-204 16 mg/kg on day 1 with a 71 day follow-up period.</description>
        </group>
        <group group_id="P5">
          <title>ETI-204 20 mg/kg</title>
          <description>Participants received a single intravenous dose of ETI-204 20 mg/kg on day 1 with a 71 day follow-up period.</description>
        </group>
        <group group_id="P6">
          <title>ETI-204 24 mg/kg</title>
          <description>Participants received a single intravenous dose of ETI-204 24 mg/kg on day 1 with a 71 day follow-up period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cohort 1 - ETI-204 4 mg/kg or Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 2 - ETI-204 8 mg/kg or Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 3 - ETI-204 16 mg/kg or Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 4 - ETI-204 20 mg/kg or Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 5 - ETI-204 24 mg/kg or Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>IM
Placebo: Placebo comparator</description>
        </group>
        <group group_id="B2">
          <title>ETI-204</title>
          <description>IM
ETI-204: monoclonal antibody</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.8" spread="11.53"/>
                    <measurement group_id="B2" value="47.4" spread="14.31"/>
                    <measurement group_id="B3" value="47.0" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.71" spread="13.406"/>
                    <measurement group_id="B2" value="76.33" spread="12.351"/>
                    <measurement group_id="B3" value="74.2" spread="12.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.18" spread="8.859"/>
                    <measurement group_id="B2" value="171.01" spread="8.062"/>
                    <measurement group_id="B3" value="169.3" spread="8.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.92" spread="2.983"/>
                    <measurement group_id="B2" value="26.04" spread="3.454"/>
                    <measurement group_id="B3" value="25.76" spread="3.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Adverse Events</title>
        <description>Safety was assessed for all subjects in the Safety Population by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical examinations, injection site assessments, skin assessments for presence/absence of rash, and adverse events (AEs).</description>
        <time_frame>Up to 71 (+/- 4) days or for 30 additional days after the final study visit for subjects with ongoing adverse events at the final scheduled study visit, for each group.</time_frame>
        <population>All subjects who received either ETI-204 or placebo were included in the Safety Population. Placebo subject were included in each cohort (one in Cohort 1 and two each in Cohorts 2, 3 ,4 and 5). Safety data are summarized separately for subjects who received ETI-204 in each dose group and for the pooled placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>ETI-204 placebo IM</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>4 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>8 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>16 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>20 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>24 mg/kg ETI-203 IM</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Adverse Events</title>
          <description>Safety was assessed for all subjects in the Safety Population by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical examinations, injection site assessments, skin assessments for presence/absence of rash, and adverse events (AEs).</description>
          <population>All subjects who received either ETI-204 or placebo were included in the Safety Population. Placebo subject were included in each cohort (one in Cohort 1 and two each in Cohorts 2, 3 ,4 and 5). Safety data are summarized separately for subjects who received ETI-204 in each dose group and for the pooled placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration of ETI-204 (Cmax)</title>
        <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
        <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
        <population>The Pharmacokinetic (PK) Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. One subject in Cohort 2 was excluded from the PK Population because the dosing record was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>8 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>16 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>20 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>24 mg/kg ETI-204 IM</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration of ETI-204 (Cmax)</title>
          <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
          <population>The Pharmacokinetic (PK) Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. One subject in Cohort 2 was excluded from the PK Population because the dosing record was missing.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="4.70"/>
                    <measurement group_id="O2" value="54.8" spread="6.45"/>
                    <measurement group_id="O3" value="105" spread="22.5"/>
                    <measurement group_id="O4" value="118" spread="28.2"/>
                    <measurement group_id="O5" value="154" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration of ETI-204 (Tmax)</title>
        <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
        <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
        <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. One subject in Cohort 2 was excluded from the PK Population because the dosing record was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>8 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>16 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>20 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>24 mg/kg ETI-204 IM</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration of ETI-204 (Tmax)</title>
          <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
          <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. One subject in Cohort 2 was excluded from the PK Population because the dosing record was missing.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="3.00" upper_limit="9.00"/>
                    <measurement group_id="O2" value="9.00" lower_limit="3.00" upper_limit="9.00"/>
                    <measurement group_id="O3" value="6.00" lower_limit="6.00" upper_limit="14.00"/>
                    <measurement group_id="O4" value="6.00" lower_limit="6.00" upper_limit="14.00"/>
                    <measurement group_id="O5" value="6.00" lower_limit="3.00" upper_limit="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last)</title>
        <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
        <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
        <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. One subject in Cohort 2 was excluded from the PK population because the dosing record was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>8 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>16 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>20 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>24 mg/kg ETI-204 IM</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last)</title>
          <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
          <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. One subject in Cohort 2 was excluded from the PK population because the dosing record was missing.</population>
          <units>µg.day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774" spread="92.3"/>
                    <measurement group_id="O2" value="1540" spread="328"/>
                    <measurement group_id="O3" value="2890" spread="578"/>
                    <measurement group_id="O4" value="3660" spread="945"/>
                    <measurement group_id="O5" value="3740" spread="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)</title>
        <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
        <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
        <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. 1 subject in Cohort 2 was excluded because the dosing record was missing. For 4 subjects (1 in Cohort 2, 1 in Cohort 4. and 2 in Cohort 5) the extrapolated portion of AUC0-inf was &gt;20%; therefore, AUC0-inf was not recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>8 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>16 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>20 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>24 mg/kg ETI-204 IM</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)</title>
          <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
          <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. 1 subject in Cohort 2 was excluded because the dosing record was missing. For 4 subjects (1 in Cohort 2, 1 in Cohort 4. and 2 in Cohort 5) the extrapolated portion of AUC0-inf was &gt;20%; therefore, AUC0-inf was not recorded.</population>
          <units>µg.day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="819" spread="85.9"/>
                    <measurement group_id="O2" value="1580" spread="441"/>
                    <measurement group_id="O3" value="3200" spread="755"/>
                    <measurement group_id="O4" value="4220" spread="1360"/>
                    <measurement group_id="O5" value="3960" spread="823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life (t1/2)</title>
        <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
        <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
        <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. One subject in Cohort 2 was excluded from the PK Population because the dosing record was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>8 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>16 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>20 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>24 mg/kg ETI-204 IM</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t1/2)</title>
          <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
          <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter. One subject in Cohort 2 was excluded from the PK Population because the dosing record was missing.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="1.60"/>
                    <measurement group_id="O2" value="20.2" spread="8.47"/>
                    <measurement group_id="O3" value="19.6" spread="4.10"/>
                    <measurement group_id="O4" value="23.3" spread="6.17"/>
                    <measurement group_id="O5" value="20.0" spread="7.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F)</title>
        <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
        <time_frame>Pre-dose and 1.5, 4, 8, 24, 36, 48, 72 hours after the IM injection of ETI-204 on Day 1, and on Days (7), 10, 15, 29, 43, and 71. A Day 7 sample was not included in the profile until the dose had escalated to 20 mg/kg.</time_frame>
        <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter.1 subject in Cohort 2 was excluded because the dosing record was missing. For 4 subjects (1 in Cohort 2, 1 in Cohort 4, and 2 in Cohort 5) the extrapolated portion of AUC0-inf was &gt;20%; therefore, AUC0-inf-based parameters were not recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>8 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>16 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>20 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>24 mg/kg ETI-204 IM</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F)</title>
          <description>Blood samples were obtained and serum concentrations were determined for free ETI-204 using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.</description>
          <population>The PK Population consisted of all subjects who received ETI-204 IM and had at least one valid PK parameter.1 subject in Cohort 2 was excluded because the dosing record was missing. For 4 subjects (1 in Cohort 2, 1 in Cohort 4, and 2 in Cohort 5) the extrapolated portion of AUC0-inf was &gt;20%; therefore, AUC0-inf-based parameters were not recorded.</population>
          <units>Liters/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.410" spread="0.0545"/>
                    <measurement group_id="O2" value="0.415" spread="0.117"/>
                    <measurement group_id="O3" value="0.445" spread="0.113"/>
                    <measurement group_id="O4" value="0.382" spread="0.0736"/>
                    <measurement group_id="O5" value="0.478" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-ETI-204 Antibodies</title>
        <description>Blood samples were collected and serum samples were assayed at an initial dilution of 1:10. Samples that were positive at the 1:10 dilution were serially diluted 1:2 and assayed until a negative result was attained. The titer of the most dilute sample yielding a positive result was recorded as the titer for that time point. Immunogenicity was measured by the number of participants in each study arm with anti-ETI-204 antibody values at Days 8, 43 or 71 ≥ 4-times higher than at baseline, or if the titer was negative at baseline, the post-treatment sample(s) required a titer of at least 1:20 for it to be considered positive.</description>
        <time_frame>Pre-dose and on Days 10, 43, and 71 after the IM injection of ETI-204 or placebo on Day 1.</time_frame>
        <population>All subjects in the Safety Population who received either ETI-204 IM or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>ETI-204 Placebo IM</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>4 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>8 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>16 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>20 mg/kg ETI-204 IM</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>24 mg/kg ETI-204 IM</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-ETI-204 Antibodies</title>
          <description>Blood samples were collected and serum samples were assayed at an initial dilution of 1:10. Samples that were positive at the 1:10 dilution were serially diluted 1:2 and assayed until a negative result was attained. The titer of the most dilute sample yielding a positive result was recorded as the titer for that time point. Immunogenicity was measured by the number of participants in each study arm with anti-ETI-204 antibody values at Days 8, 43 or 71 ≥ 4-times higher than at baseline, or if the titer was negative at baseline, the post-treatment sample(s) required a titer of at least 1:20 for it to be considered positive.</description>
          <population>All subjects in the Safety Population who received either ETI-204 IM or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 71 (+/- 4) days or for 30 additional days after the final scheduled study visit for subjects with ongoing adverse events at that visit, for each group.</time_frame>
      <desc>Monitoring of Vital signs, clinical laboratory values, ECGs, physical examinations, and adverse events at each scheduled study visit. Skin assessment for presence or absence of rash was performed predose and 1, 2, 4, 12, 24, 48, and 72 hours after the IM injection on Day 1. A Visual Analog Scale for self-evaluation of pain was administered within 0-5 minutes after the IM injection on Day 1 and 2, 4, 8, 24, 48 and 72 hours after the injection.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>ETI-204 Placebo IM</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1</title>
          <description>4 mg/kg ETI-204 IM</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2</title>
          <description>8 mg ETI-204 IM</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3</title>
          <description>16 mg/kg ETI-204 IM</description>
        </group>
        <group group_id="E5">
          <title>Cohort 4</title>
          <description>20 mg/kg ETI-204 IM</description>
        </group>
        <group group_id="E6">
          <title>Cohort 5</title>
          <description>24 mg/kg ETI-204 IM</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lip Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation Irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The data generated in this clinical study are the exclusive property of the Sponsor. Written approval from the Sponsor is required prior to disclosing any information related to this clinical study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director of Regulatory</name_or_title>
      <organization>Elusys Therapeutics, Inc.</organization>
      <phone>973-808-0222</phone>
      <email>cdillon@elusys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

